GlassScriptPhysician profile
Samual Francis
NPI 1861804148
$9,728.65
in general payments reported to CMS, 2019-2025
40 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,498 · 2020: $211 · 2021: $55.73 · 2022: $424 · 2023: $1,248 · 2024: $2,120 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,539.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,228.29 | 2019-2021 | |
| Daiichi Sankyo INC. | $1,265.30 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $825.10 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $631.44 | 2022-2025 | Libtayo, Lynozyfic |
| Astrazeneca Pharmaceuticals LP | $394.34 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Exelixis INC. | $393.14 | 2021-2025 | Cabometyx |
| Sobi, INC | $241.98 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $221.93 | 2022-2023 | Pylarify |
| Servier Pharmaceuticals LLC | $219.34 | 2023-2025 | |
| Hologic INC | $211.42 | 2020 | |
| Novocure INC. | $163.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $150.42 | 2023-2024 | Opdivo, Opdualag |
| Incyte Corporation | $140.18 | 2022-2025 | Jakafi, Niktimvo |
| Janssen Biotech, INC. | $136.62 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Sumitomo Pharma America, INC. | $130.34 | 2024-2025 | Orgovyx |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Icotec Medical INC. | $123.74 | 2024 | Vader Pedicle System |
| Celgene Corporation | $118.08 | 2022-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $107.63 | 2022-2024 | |
| Beigene USA, INC. | $101.02 | 2024-2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $95.68 | 2024-2025 | Keytruda, Lenvima |
| Pfizer INC. | $84.39 | 2022-2024 | |
| Emd Serono, INC. | $71.57 | 2024-2025 | |
| Amgen INC. | $69.18 | 2022-2023 | Lumakras |
| Stemline Therapeutics INC. | $67.35 | 2023-2025 | Orserdu |
| Beone Medicines USA, INC. | $60.11 | 2025 | Brukinsa |
| Seagen INC. | $52.90 | 2023 | Padcev, Tukysa |
| Geron Corporation | $50.53 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $45.93 | 2024-2025 | Fruzaqla |
| Coherus Oncology, INC. | $40.37 | 2024 | |
| Genentech USA, INC. | $38.20 | 2024-2025 | Tecentriq, Polivy |
| Genmab U.S., INC. | $36.08 | 2023-2025 | Tivdak, Epkinly |
| Astellas Pharma US INC | $30.40 | 2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $29.31 | 2023 | Onivyde, Somatuline Depot |
| Reflexion Medical, INC. | $25.00 | 2023 | Reflexion Medical Radiotherapy System |
| Sun Pharmaceutical Industries INC. | $23.57 | 2023 | Odomzo, Yonsa |
| Array Biopharma INC | $23.25 | 2024 | Braftovi |
| Agios Pharmaceuticals, INC. | $22.14 | 2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $21.72 | 2025 | Jemperli |
| Morphosys, US INC. | $19.01 | 2023 | Monjuvi |
| Sirtex Medical INC | $18.49 | 2023 | Sir-Spheres Microspheres |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samual Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.